
|Articles|October 28, 2014
- Gastrointestinal Cancers (Issue 3)
- Volume 3
- Issue 1
Unanswered Questions Regarding the Treatment of Pancreatic NETs
Author(s)James C. Yao, MD
James C. Yao, MD, gives an overview of the questions that still remain regarding the treatment of pancreatic neuroendocrine tumors (NETs).
Advertisement
James C. Yao, MD, professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, gives an overview of the questions that still remain regarding the treatment of pancreatic neuroendocrine tumors (NETs).
Read more about the treatment of pancreatic NETs > >
Articles in this issue
about 11 years ago
Targeted Agents and Combinations Being Studied in Pancreatic NETsabout 11 years ago
Sequencing Agents for the Treatment of Pancreatic NETsabout 11 years ago
Research on Epidemiology of GIST Identifies Risk Factorsabout 11 years ago
Antiangiogenic Strategies for mCRC Need Further Explorationabout 11 years ago
Coping With Comorbidities in Hepatocellular Cancerabout 11 years ago
Strategies in Surveillance: Hepatocellular Carcinomaabout 11 years ago
Immunotherapy and Viral Therapy for Pancreatic CancerAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia
2
FDA Approves Novel Interchangeable Biosimilar for Pertuzumab in HER2+ Breast Cancer
3
Rethinking Advanced Prostate Cancer: Surprising Finds from a Landmark Study
4
How Resting Immune Cells Could Be the Key to Fighting Prostate Cancer
5









































